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For personalAbstract Background: The role of maternal serum triglycerides (TGs) in the development of
fetal macrosomia in different subgroups of body mass index (BMI) has received little attention.
The aim of this study was to determine the association between the level of maternal TGs and
fetal macrosomia in Iranian pregnant women of different BMI subgroups with gestational
diabetes mellitus (GDM).
Methods: This cohort study was conducted on 305 pregnant women with GDM referred for
glucose control to Kowsar Hospital in Qazvin, Iran. Level of TGs was measured on the 24th
e28th weeks of pregnancy. The ROC curve of the level of TGs was depicted in BMI subgroups
to predict fetal macrosomia. Logistic regression analysis was used to determine the risk of
macrosomia per 1-SD increase in the level of TGs.
Results: The prevalence of hypertriglyceridemia did not significantly differ across BMI
subgroups. Macrosomia was more prevalent in obese women (32.2%) than overweight (19.1%)
and normal weight (11.1%) women (P < 0.05). A 1-SD increase in the level of TG was associated
with 4.2 and 1.9 times increased risk of macrosomia in normal weight (P < 0.01) and
overweight (P < 0.01) women, respectively. Serum level of TGs was not associated with macro-
somia in any adjustment models in obese women. The area under the curve of the level of TGs
for macrosomia was 0.828 (95% CI: 0.712e0.911, P < 0.001) and 0.711 (95% CI: 0.639e0.775,
P < 0.001) in normal weight and overweight women, respectively.
Conclusion: Hypertriglyceridemia was a predictor of macrosomia in non-obese women. More
studies on different ethnicities and lifestyles are necessary to determine the association
between the level of maternal TG and fetal macrosomia in BMI subgroups.seases Research Center, Booali-Sina Hospital, Booali-Sina Street, Qazvin, Iran. Fax: þ98 28 33326033.
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Macrosomia is the main complication of gestational dia-
betes mellitus (GDM), associated with important neonatal
complications such as birth trauma, hypoglycemia, and
hematologic and respiratory complications.1,2 The compli-
cations of macrosomia are not limited to the neonatal
period and fetal macrosomia is a major risk factor for
obesity and type 2 diabetes mellitus in adolescence and
young adulthood.3
For decades, the occurrence of macrosomia has been
attributed to high maternal blood glucose. With regards to
the Pedersen hypothesis, excess maternal glucose transfers
through the placenta and stimulates islet cells and hyper-
insulinemia, resulting in macrosomia.4
Although macrosomia has been associated with maternal
blood glucose,5,6 the results of previous studies are incon-
sistent.7,8 Despite appropriate glycemic control in many
pregnant women with GDM, macrosomia is still prevalent
and is often linked to unrecognized maternal hyperglyce-
mia. However, the risk of macrosomia is higher in well
controlled GDM confirmed by continuous glucose monitoring
(CGM) than the general population.9 The association
between fetal macrosomia and age, obesity, previous his-
tory of macrosomia, and hypertriglyceridemia has been
showed previously.10
The association between maternal hypertriglyceridemia
and birth weight has been reported in pregnant women with
and without GDM.10e15 In a study by Schaefer-Graf et al.,
maternal hypertriglyceridemia has been a stronger predic-
tor of macrosomia than glycemic control in pregnant women
with GDM.15 Maternal obesity also has an independent
role in the development of macrosomia.16 The meta-analysis
conducted by Gaudet et al. revealed that maternal obesity
was associated with a two-times increased risk of
macrosomia.17
However, the role of serum triglycerides (TGs) in the
development of fetal macrosomia in different subgroups of
body mass index (BMI) has been neglected. In a study by
Olmos et al., serum triglycerides level was not associated
with birth weight in normal weight women with GDM, while
the level of maternal TGs was correlated with birth weight in
obese and overweight pregnant women.12 With regards to
the role of ethnicity in lipid profile status in pregnant
women18 and limited studies on BMI categories, the aim of
this study was to determine the association between
maternal hypertriglyceridemia and fetal macrosomia in Ira-
nian pregnant women of different BMI subgroups with GDM.2. Methods
This cohort study was conducted on 319 pregnant women
with GDM referred for glucose control to Kowsar hospital in User (n/a) at Iran University of Medical S
e only. No other uses without permission. CQazvin, Iran, from January 2015 to March 2016. The study
protocol was approved by the Ethics Committee of Qazvin
University of Medical Sciences. This study was conducted
according to the guidelines laid down in the Declaration of
Helsinki, and all participants gave their written informed
consent forms.
The inclusion criteria were being 16e40 years old,
singleton pregnancy, gestational age of 24e28 weeks, and
positive 75 g oral glucose tolerance test results (fasting
blood glucose 92 mg/dL and/or 1 h blood glucose
180 mg/L or/and 2 h blood glucose 153 mg/dL).
The exclusion criteria were chronic renal, thyroid, or liver
disease; rheumatologic diseases, e.g. SLE and anti-
phospholipid syndrome; a history of anticonvulsive drugs
and opium use; smoking; and congenital fetal anomalies in
ultrasonography. Pregnant women with hypertension and
pre-eclampsia were also excluded from the study.
BMI was calculated using the self-reported height and
weight of the pre-pregnancy period. A BMI less than 25 was
considered normal. Obesity was defined as BMI  30 and
overweight was defined as 25  BMI < 30. Gestational age
was determined using previous pregnancy ultrasound
results. Excessive weight gain was defined as a weight gain
of more than 16 kg during pregnancy.19
At 24the28th weeks of pregnancy, serum level of TGs
was measured after a 12 h overnight fasting using the
enzymatic colorimetric method and reagent (Pars Azmoon
Co, Iran). Inter-assay and intra-assay coefficients of varia-
tion were 1.6% and 1.47%, respectively. In the last weeks of
pregnancy, fasting blood glucose and 2 hr postprandial
glucose were recorded over phone calls. Birth weight was
recorded according to the registered birth documents.
A birth weight  4000 g was considered as macrosomia.20
2.1. Statistical analysis
Data were described as mean  SD or frequency where
appropriate. Parameters related to macrosomia were
compared among BMI subgroups using ANOVA with Tukey’s
pot-hoc test. Logistic regression analysis was used to
determine the risk of macrosomia per 1-SD increase in the
level of TGs as the predictor variable, and two models were
applied for adjustment. In the first model, significant vari-
ables in the univariate analysis unrelated to diabetes
(gestational age at delivery and maternal age > 35 years)
were considered as the covariate. In the second model,
variables related to diabetes (insulin use, fasting blood
glucose at diagnosis, mean fasting blood glucose, and 2 hr
postprandial glucose in the last weeks of pregnancy) were
considered as the covariate in addition to the first-model
variables. To facilitate the comparison with Olmos et al.’s
study,12 similar criteria were applied to define hyper-
triglyceridemia using the normal values of TGs in the preg-
nancy period published by Alvarez et al.21 The 90thciences from ClinicalKey.com by Elsevier on August 28, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
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pregnancy was calculated as mean þ 1.28 SD based on
Alvarez et al.’s study and considered as the optimal
cut-point to determine hypertriglyceridemia. Therefore,
the 90th percentile of the level of TGs in the third trimester
of pregnancy was 273 mg/dL.
The Receiver operating characteristic (ROC) curve of the
level of TGs for the diagnosis of fetal macrosomia was
depicted in the BMI subgroups separately and the area
under the curve (AUC) was calculated. The optimal
cut-point of the level of TGs to predict fetal macrosomia
was assessed by maximum Youden index [sensitivity e (1-
specificity)] on the ROC curve. P-values < 0.05 were
considered as statistically significant.3. Results
Of 319 pregnant women with GDM, 63 normal weight, 183
overweight, and 59 obese pregnant women completed the
study. Fasting and postprandial blood glucose levels in the
last weeks of pregnancy were available for 229 pregnant
women. The baseline characteristics of lost subjects
(age, TGs, fasting blood glucose, and insulin use) were not
significantly different from those of other subjects. The
results of birth weight in 14 pregnant women were lost due
to delivery in other cities.
The clinical and biochemical characteristics of the study
subjects are shown in Table 1. Gestational age at delivery
significantly differed across the three groups. The longest
and shortest gestational age was found in the normal weight
group and obese group, respectively. The frequency of
maternal age > 35 years was significantly higher in theTable 1 Clinical and biochemical characteristics of the study s
Variable Normal weight(n Z 63)
Maternal
Age (yr)a 30.4  5.3
Age >35 years (%) 23.8%
Gestational age at delivery (weeks)a 38.6  0.9
Body Mass Index (Kg/m2)a 23.5  1.4
Weight gain (Kg) 14.1  2.2
Excessive weight gain (%)b 13.7%
Triglycerides (mg/dL)a 270.3  65.3
Hypertriglyceridemia (%)c 44.4%
FBS (mg/dL)a 106.6  10.5
Third trimester FBS (mg/dL)a 96.6  9.5
Third trimester BS 2hpp (mg/dL)a 119.4  13.7
Insulin treatment (%) 46.8%
Neonatal
Birth weight (g)a 3313.7  410.3
Fetal macrosomia (%) 11.1%
FBS: Fasting blood glucose; BS: Blood glucose.
* Significant difference between overweight group and normal and ob
** Significant difference among the three groups.
*** Significant difference between normal weight group and overweig
**** Significant difference between obese groups and normal weight a
a Data are presented as mean  SD.
b Weight gain > 16 kg during pregnancy.
c Hypertriglyceridemia was defined based on the 90th percentile of n
study (21).
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(P Z 0.011). Mean weight gain and frequency of excessive
weight gain during pregnancy were not significantly
different among the three groups. Mean level of TGs, fasting
blood glucose at GDM diagnosis, fasting and postprandial
blood glucose in the last weeks of pregnancy, and preva-
lence of hypertriglyceridemia and insulin treatment were
not different between the three BMI subgroups. After
delivery, macrosomia was more prevalent in obese women
compared to the other groups (32.2% vs. 19.1% in overweight
women and 11.1% in normal weight women, P < 0.05).
The results of logistic regression analysis of the rela-
tionship between a 1-SD increase in the level of TGs as the
independent factor and fetal macrosomia as the dependent
factor are demonstrated in Table 2. In the univariate
analysis, a 1-SD increase in the level of TGs was only
associated with the increased risk of macrosomia in normal
weight and overweight pregnant women. In Model 1
(adjusted for gestational age at delivery and maternal
age > 35 years), a 1-SD increase in the level of TGs was
associated with 3.4 times (P < 0.05) and 1.9 times
(P < 0.01) increased risks of macrosomia in normal weight
and overweight women, respectively. In the normal weight
group, serum level of TGs remained an independent risk
factor of macrosomia after adjusting for insulin use, fasting
blood glucose at diagnosis, mean fasting blood glucose, and
2 hr postprandial glucose in the last weeks of pregnancy.
Nevertheless, serum level of TGs was not associated with
macrosomia in any models applied for obese women.
The AUC of the level of TGs for macrosomia was 0.828
(95% CI: 0.712e0.911, P < 0.001) in normal weight women,
0.711 (95% CI: 0.639e0.775, P < 0.001) in overweight
women, and 0.549 (95% CI: 0.414e0.679, PZ 0.53) in obeseubject.
Overweight(n Z 183) Obese(n Z 59) P-value
30.7  4.0 31.7  4.3 0.231
11.5% 25.4% 0.011*
38.2  1.2 37.8  1.1 0.001**
27.5  1.2 32.5  2.7 <0.001**
13.8  2.4 13.7  2.8 0.767
11% 12.5% 0.860
278.2  67.3 298.5  89.6 0.08
51.4% 55.9% 0.435
109.9  12.7 109.2  12.2 0.127
97.2  8.5 99.6  10.2 0.266
118.3  11.6 119.0  13.5 0.866
48.3% 46.2% 0.688
3475.6  512.3 3538.1  626.8 0.04***
19.1% 32.2% 0.013****
ese groups.
ht and obese groups.
nd overweight groups.
ormal values in the third trimester of pregnancy in Alvarez et al.’s
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Table 2 Logistic regression analysis of the relationship
between 1-SD increase in the level of TGs as the indepen-
dent factor and fetal macrosomia as the dependent factor.
Group Crude OR Model 1 Model 2
Normal
weight
4.2 (1.5
e12.1)**
3.4 (1.1
e10.6)*
16.7 (1.2
e130.9.)*
Overweight 1.9 (1.3
e2.9)**
1.9 (1.3
e2.8)**
1.5 (0.9e2.5)
Obese 1 (0.6e1.6) 0.9 (0.6e1.5) 0.9 (0.5e1.9)
Model 1: Adjusted for gestational age at delivery and maternal
age >35 years.
Model 2: Adjusted for Model 1 variables + insulin use, FBS at
diagnosis, mean FBS in the third trimester, and mean BS 2hpp in
the third trimester.
*P < 0.05, **P < 0.01.
570 S. Hashemipour et alwomen. The optimal cut-off of TGs for macrosomia was
300 mg/dL in normal weight women (sensitivity: 85.7%,
specificity: 73.2%) and 282 mg/dL in overweight women
(sensitivity: 77.1%, specificity: 62.8%).
4. Discussion
In the present study, the incidence of fetal macrosomia was
about three times and two times higher in obese women
than normal weight and overweight women, respectively. A
1-SD increase in the level of maternal TGs at the beginning
of the third trimester of pregnancy was associated with a
four-times increased risk of macrosomia in normal weight
women and with 1.5-times increased risk of macrosomia in
overweight women. The level of TGs had an independent
association with macrosomia after adjustment for known
risk factors of macrosomia. In normal weight women, serum
TGs greater than 300 mg/dL could predict macrosomia with
85.7% sensitivity and 73.2% specificity. The level of TGs was
not associated with macrosomia in obese women.
In previous studies, the level of maternal TGs had an
independent and strong association with birth weight in
pregnant women with and without GDM.1015 There are
some pathophysiological reasons for the increased risk of
macrosomia in pregnant women with hypertriglyceridemia.
Serum level of TGs is subject to significant changes in
pregnancy trimesters. In the first trimester of pregnancy,
insulin sensitivity and lipoprotein lipase activity increase.
The lipoprotein lipase activity decreases in the third
trimester of pregnancy due to the increase in insulin
resistance, a phenomenon which is more prominent in GDM.
Maternal lipoproteins will not cross the placenta but are
hydrolyzed by placental lipoprotein lipase. The derived
fatty acids enter the umbilical cord blood, are stored in
fetal adipose tissues, and result in increased fetal growth
and adiposity.22
There are limited reports on the association of the level
of TGs in pregnant women and macrosomia in BMI
subgroups. In a study by Olmos et al., z-scores of TGs had a
significant correlation with birth weight z-scores in over-
weight and obese pregnant women (rZ 0.42 and rZ 0.47,
P < 0.001, respectively), while there was no such cor-
relation in normal weight women.12 These results areDownloaded for Anonymous User (n/a) at Iran University of Medical S
For personal use only. No other uses without permission. Cconsiderably different from the results of the present
study. In Olmos et al.’s study, the level of TGs and preva-
lence of hypertriglyceridemia was significantly lower in
lean women than overweight and obese women. Never-
theless, these values did not differ across normal weight
and overweight or obese women in the present study. Mean
level of TGs in normal weight women was 229  67.3 mg/dL
in Olmos et al.’s study that is lower than the value
reported in the present study. Based on the 90th percentile
of Alvarez et al.’s study, the prevalence of hyper-
triglyceridemia was 44.4% in the present study compared to
34% in Olmos et al.’s study.12 The lower prevalence of
hypertriglyceridemia in normal weight women in Olmos
et al.’s study can explain the insignificant correlation be-
tween the level of TGs and macrosomia due to the lower
power in this BMI subgroup.
Differences in the serum level of TGs in normal weight
women between Olmos et al.’s12 study and the present
study may be due to the differences in ethnicity and life-
style. In another study conducted in Qazvin, the prevalence
of insulin resistance in normal weight women was very high
(about 40%) and hypertriglyceridemia was the strongest
predictor of normal weight metabolic obesity in women.23
In the present study, the incidence of macrosomia in
obese women was high (30%), approximately three times
more than that of normal weight women. Gestational age at
delivery was significantly different among the three groups,
and the frequency of maternal older age was significantly
lower in the overweight group. However, the association
between hypertriglyceridemia and macrosomia was still not
significant in obese women after adjustment for variables
unrelated to diabetes in Model 1 and other variables related
to blood glucose control in Model 2. The reason for this
finding and the difference with Olmos et al.’s study12 is
unclear. Considering the high incidence rate of macrosomia
in obese women in the present study, it seems that other
stronger factors may be involved in the development of
macrosomia in obese pregnant women with GDM.
In the present study, despite the significant difference in
the incidence of macrosomia among the three groups,
blood glucose at GDM diagnosis and insulin therapy rate
were not different among the groups. Blood glucose in the
last weeks of pregnancy was missed in 25% of study
participants. It can be suggested that the glycemic control
in the obese group has probably been worse than the non-
obese group. However, mean blood glucose at GDM
diagnosis and insulin therapy rate were not different be-
tween participants with missed blood glucose in the last
weeks of pregnancy compared with other participants.
Therefore, there is no evidence for a worse glycemic
control in obese women with missed blood glucose in the
last weeks of pregnancy.
In addition to lipids and glucose, amino acids, glycerol,
and keton bodies play a role in fetal growth.24 In Aye
et al.’s study, an increase in placental p33-mitogen-acti-
vated protein kinase (MAPK) phosphorylation was found in
obese women, a phenomenon which correlated with fetal
growth. They hypothesized that increased inflammatory
mediators in obese pregnant women induce an increase in
MAPK phosphorylation that leads to an increase in the
transfer of nutrients (e.g. amino acids) to the placenta and
development of macrosomia.25ciences from ClinicalKey.com by Elsevier on August 28, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
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decrease in peroxisome proliferator-activated receptor-a
(PPARa) phosphorylation in the placenta was associated with
an increase in the transfer of amino acids and glucose and a
29% increase in fetal weight. The mentioned changes and
fetal weight were returned to normal after the administration
of adiponectin to mothers. Therefore, a decrease in adipo-
nectin in obese women can play a role in fetal macrosomia.
There are reports that placental lipoprotein lipase
increases, inflammatory cells (e.g. macrophages and neu-
trophils) accumulate, and the expression of inflammatory
inhibitors (e.g. TNF-a, IL-1, and IL-6) increases in the
placenta of obese women.27 The effect of IL-6 on the
accumulation of fatty acids has also been reported in
cultured human trophoblast.28 In addition, vascular changes
in the placenta of obese women can potentially increase the
transfer of nutrients through the placenta.29 With regards to
the noted studies, the high prevalence of macrosomia in
obese women is multifactorial and cannot be attributed to a
single factor such as hypertriglyceridemia.
In the present study, the optimal cut-point of TGs was
300 mg/dL in normal weight women and 287 mg/dL in
overweight women. In Son et al.’s study11 on pregnant
women with GDM, the optimal cut-point of TGs (294 mg/dL)
was similar to that of the present study with 48% sensitivity
and 83.5% specificity, but sensitivity and specificity were
not evaluated in BMI subgroups.
The main limitation of the present study was the missed
blood glucose in the last weeks of pregnancy in 25% of the
participants. Nevertheless, mean fasting blood glucose in
the second trimester of pregnancy and frequency of insulin
therapy in this group were not different from those of other
participants. BMI classification was based on pre-pregnancy
values self-reported by pregnant women. Still, the accu-
racy of self-reported BMI for evaluating diseases and their
complications was appropriate in the study by McAdams
et al.30 The strength of the present study was studying a
population with special metabolic disturbances including
high insulin resistance in the normal weight population and
the new finding of lack of association between the level of
maternal TGs and macrosomia in obese subjects.
In summary, the prevalence of hypertriglyceridemia
did not significantly differ among normal weight and
obese or overweight women with GDM. Although hyper-
triglyceridemia was a strong predictor of macrosomia in
normal weight women, its association with macrosomia was
weak in overweight women. There was no association be-
tween hypertriglyceridemia and macrosomia in obese
women. With regards to the difference between the results
of the present study and those of previous studies, more
studies on various ethnicities and lifestyles are necessary.Conflict of interest
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